

Application No. 10/699,393  
 Response Dated October 24, 2006  
 Reply to Office Action of August 24, 2006

**BEST AVAILABLE COPY**

### Exhibit A

**The invention Shows Synergistic Results**  
 (From Tables 1 and 2, see Specification, pages 48 and 50)

Property	E217A	W215A	WE
<b>PA/FC *</b>	40.06	170	2865
<b>Fibrinogen</b> $k_{cat}/K_m$ ( $\mu\text{M}^{-1}\text{s}^{-1}$ )	0.27	0.034	0.00089
<b>Fibrin</b> $k_{cat}/K_m$ ( $\mu\text{M}^{-1}\text{s}^{-1}$ )	0.15	0.053	0.0021
<b>Protein C + TM</b> $k_{cat}/K_m$ ( $\mu\text{M}^{-1}\text{s}^{-1}$ )	0.14	0.075	0.033
<b>PAR1</b> $k_{cat}/K_m$ ( $\mu\text{M}^{-1}\text{s}^{-1}$ )	0.66	1	0.026
<b>Antithrombin III</b> $k_{on}$ ( $\mu\text{M}^{-1}\text{s}^{-1}$ ) <sup>d</sup>	1	0.56	0.0040

\*The PA/FC here are calculated from the data shown in Tables 1 and 2. The term "PA/FC ratio" as used herein refers to the ratio of the percent of wild-type protein C activation (PA) activity remaining in a thrombin variant relative to the percent of wild-type fibrinogen clotting (FC) activity remaining in the thrombin variant. A value of PA/FC greater than 1.0 indicates that the thrombin variant has reduced procoagulant fibrinogen cleavage activity relative to the residual anticoagulant activity resulting from protein C activation. See Specification 16.

### Comparative Data Between Cited References and the Invention

Property	The Primary Reference E229A (E217A)	The Secondary Reference W215A	The Invention WE
<b>PA/FC *</b>	19.1	170	2865

Annual Review of  
Pathology: Mechanisms of Disease

Sign up for PNAS Online eToC

Get notified by email when  
new content goes on-line

AB#111

[Info for Authors](#) | [Editorial Board](#) | [About](#) | [Subscribe](#) | [Advertise](#) | [Contact](#) | [Site Map](#)

PNAS  
Proceedings of the National Academy of Sciences of the United States of America

NO

[◀ Previous Article](#) | [Table of Contents](#) | [Next Article ▶](#)

Proceedings of the National Academy of Sciences, Vol 92, 5977-5981,  
Copyright © 1995 by National Academy of Sciences

## ARTICLE

# An Allosteric Switch Controls the Procoagulant and Anticoagulant Activities of Thrombin

QD Dang, A Vindigni and ED Cera

Thrombin is an allosteric enzyme existing in two forms, slow and fast, that differ widely in their specificities toward synthetic and natural amide substrates. The two forms are significantly populated in vivo, and the allosteric equilibrium can be affected by the binding of effectors and natural substrates. The fast form is procoagulant because it cleaves fibrinogen with higher specificity; the slow form is anticoagulant because it cleaves protein C with higher specificity. Binding of thrombomodulin inhibits cleavage of fibrinogen by the fast form and promotes cleavage of protein C by the slow form. The allosteric properties of thrombin, which has targeted two distinct conformational states toward its two fundamental and competing roles in hemostasis, are paradigmatic of a molecular strategy that is likely to be exploited by other proteases in the blood coagulation cascade.

### This Article

- ▶ [Full Text \(PDF\)](#)
- ▶ [Alert me when this article is cited](#)
- ▶ [Alert me if a correction is posted](#)
- ▶ [Citation Map](#)

### Services

- ▶ [Similar articles in this journal](#)
- ▶ [Similar articles in PubMed](#)
- ▶ [Alert me to new issues of the journal](#)
- ▶ [Add to My File Cabinet](#)
- ▶ [Download to citation manager](#)
- ▶ [Cited by other online articles](#)
- ▶ [Request Copyright Permission](#)

### Google Scholar

- ▶ [Articles by Dang, Q. D.](#)
- ▶ [Articles by Cera, E. D.](#)
- ▶ [Articles citing this Article](#)

### PubMed


- ▶ [PubMed Citation](#)
- ▶ [Articles by Dang, Q. D.](#)
- ▶ [Articles by Cera, E. D.](#)
- ▶ [PubMed/NCBI databases](#)
  - [Substance via MeSH](#)

**This article has been cited by other articles in HighWire Press-hosted journals:** ([Search Google Scholar for Other Citing Articles](#))

Physiological Reviews

▶ HOME

M. J. Page and E. Di Cera



[Shopping Cart](#) [Help](#) [Contact Us](#) [Mer](#)

Abstract #2

## Resources

[Home + Quick Search](#)  
[Alphabetical Listing](#)  
[Journals by Subject](#)  
[For Authors](#)  
[For Librarians](#)  
[FAQs](#)  
[My Account](#)  
[My Files](#)  
[SARA \(Contents Alerting\)](#)  
[Support Information](#)  
[Library Recommendation Form](#)  
[Linking Options](#)

## Article



[Back To: Main](#) [Publication](#)

[Click here to recommend this](#)

### Biochemistry and Molecular Biology International

**Publisher:** Taylor & Francis

**Issue:** Volume 44, Number 1 / January 1998

**Pages:** 175 - 183

**URL:** [Linking Options](#)

**DOI:** 10.1080/15216549800201192

### Non-synergistic interactions between strong allosteric effectors and human embryonic and adult haemoglobins

Amy. E.M. McLennan<sup>A1</sup> and Thomas Brittain<sup>A1</sup>

<sup>A1</sup> Biochemistry and Molecular Biology School of Biological Sciences, University of Auckland, Auckland, New Zealand

#### Abstract:

The binding of two strong allosteric effectors (2,3 Diphosphoglycerate D.P.G., and Bezafibrate, Bzf) to both adult and the three human embryonic haemoglobins, either individually or in combination, have been studied in detail. The adult protein exhibits one binding site for D.P.G and two for Bzf. When both effectors are present simultaneously their effects are simply additive. The same qualitative pattern of binding is observed in the case of the three human embryonic haemoglobins, although with different binding constants. The lack of synergism between these effectors and the different binding affinity expressed by these proteins are discussed in terms of the known amino acid sequence differences.

#### Keywords:

haemoglobin, embryonic, allosteric, effectors

*The references of this article are secured to subscribers.*

#### Full Text Access

##### Full Text Secured

The full text of this article is secured to subscribers. To gain access, you

- ① Add this item to your shopping cart for purchase later.

[Add to Shopping Cart](#)

- ② Purchase this item now.

[Purchase Item Now](#)


- ③ Log in to verify access.

[Log In](#)

ingentaconnect

Abstract #3

# Kinetic Characterization of a T-State of *Ascaris*



## suumPhosphofructokinase with Heterotropic Negative Cooperativity by ATP Eliminated

**Authors:** Jagannatha Rao G.S.<sup>1</sup>; Cook P.F.<sup>2</sup>; Harris B.G.<sup>1</sup>

**Source:** Archives of Biochemistry and Biophysics, Volume 365, Number 2, May 1999, pp. 335-343(9)

**Publisher:** Academic Press

- [< previous article](#)
- [|](#)
- [next article >](#)
- [|](#)
- [View Table of Contents](#)

<mark item

Key:

- Free content
- New Content
- Subscribed Content
- Free Trial Content

### Abstract:

The affinity analogue, 2',3'-dialdehyde ATP has been used to chemically modify the ATP-inhibitory site of *Ascaris suum* phosphofructokinase, thereby locking the enzyme into a less active T-state. This enzyme form has a maximum velocity that is 10% that of the native enzyme in the direction of fructose 6-phosphate (F6P) phosphorylation. The enzyme displays sigmoid saturation for the substrate fructose 6-phosphate ( $S_{0.5}(\text{F6P}) = 19 \text{ mM}$  and  $n_H = 2.2$ ) at pH 6.8 and a hyperbolic saturation curve for MgATP with a  $K_m$  identical to that for the native enzyme. The allosteric effectors, fructose 2,6-bisphosphate and AMP, do not affect the  $S_{0.5}$  for F6P but produce a slight (1.5- and 2-fold, respectively) V-type activation

with  $K_a$  values (effector concentration required for half-maximal activation) of 0.40 and 0.24 mM, respectively. Their activating effects are additive and not synergistic. The kinetic mechanism for the modified enzyme is steady-state-ordered with MgATP as the first substrate and MgADP as the last product to be released from the enzyme surface. The decrease in  $V$  and  $V/K$  values for the reactants likely results from a decrease in the equilibrium constant for the isomerization of the E:MgATP binary complex, thus favoring an unisomerized form. The  $V$  and  $V/K_{F6P}$  are pH dependent with similar  $pK$  values of about 7 on the acid side and 9.8 on the basic side. The microenvironment of the active site appears to be affected minimally as evidenced by the similarity of the  $pK$  values for the groups involved in the binding site for F6P in the modified and native enzymes. Copyright 1999 Academic Press.

**Keywords:** Ascaris suum; phosphofructokinase; T-state; R-state; dialdehyde-ATP; V-type activation; allosteric effectors

**Language:** English

**Document Type:** Research article

**DOI:** 10.1006/abbi.1999.1183

**Affiliations:** 1: Department of Molecular Biology and Immunology, University of North Texas Health Science Center at Fort Worth, 3500 Camp Bowie Boulevard, Fort Worth, Texas, 76107 2: Department of Chemistry and Biochemistry, University of Oklahoma, Norman, Oklahoma, 73019

Article Access Options

The full text article is available for purchase

**\$56.97 plus tax**

The exact price (including tax) will be displayed in your shopping cart before you check out. You will be able to remove this item from your shopping cart at any time before you have completed check-out.



- [< previous article](#)
- |
- [next article >](#)
- |
- [View Table of Contents](#)

[Back to top](#)

Key:

- F** - Free content
- N** - New Content
- S** - Subscribed Content
- T** - Free Trial Content

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**